

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423

June 05, 2020

The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C-1, G- Block, Bandra - Kurla Complex, Bandra (East) Mumbai – 400 051 BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE

Scrip Code: 532983

Dear Sirs,

# Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2020.

Kindly take the above on record.

Thanking you,

Yours Sincerely, For RPG Life Sciences Limited

Rhibandera

Rajesh Shirambekar Head – Legal & Company Secretary

Encl.: as above





### RPG Life Sciences Q4'FY 20 Revenue up by 29% and Profit\* up by 4x over last year

## Full Year Revenue up by 14% and Profit\* up by 2.8x over last year

Mumbai, 5 June, 2020 : RPG Life Sciences Limited has announced its financial results for the guarter and year ended March 31<sup>st</sup>, 2020.

	YoY Net Revenue from Operations	YoY Profit*
Q4 FY 20 Highlights	Rs 88.67 crores–up from Rs 68.80 crores	Rs 8.46 crores–up from Rs 2.12 crores
Full year FY 20 Highlights	Rs 375.57 crores–up from Rs 330.16 crores	Rs 41.77 crores–up from Rs 15.05 crores

\*Profit before exceptional items and tax

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted its Q4 and Full year results. Q4 revenue is higher by 29% than the corresponding quarter last year and PBT before exceptional items has registered around 4 fold jump from Rs 2.12 crores to Rs 8.46 crores.

For full year, revenue at Rs 375.57 crores grew by 14% and PBT before exceptional item at Rs 41.77 crores was almost 2.8x times of last year.

" For the year FY2020, the company registered a turnaround performance led by the biggest contributing Domestic business, which grew over 23%, much ahead of the market growth. Product portfolio rejuvenation, focus on prescription generation and sales force effectiveness enhancement were the key contributors. Overall for the company, all 4 quarters recorded fairly consistent sales and profit performance." said Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd.

	1. EDITDA margins improved from 10.1% to 14.5%
Q4 FY20 Other Highlights	2. Domestic formulations sales grew over 22% with all major brands
(y-o-y)	registering healthy growth
	3. Global ROW Sales grew by 21%
Full year FY20 Other	1. EDITDA margins improved from 10.4% to 15.9%
Highlights (y-o-y)	2. Domestic formulations sales grew over 23% with all major brands
	registering healthy double-digit growth
	3. Global ROW Sales grew by 28%

#### RPG Life Sciences Ltd (www.rpglifesciences.com):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The Company is a research-based pharmaceutical Company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

### **RPG Enterprises (www.rpggroup.com):**

RPG Enterprises, established in 1979, is one of India's fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact: Sumeet Chatterjee Senior Vice President – Group Communications sumeet@rpg.in +91 9820340650

